4nr6
From Proteopedia
(Difference between revisions)
m (Protected "4nr6" [edit=sysop:move=sysop]) |
|||
| (5 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==Crystal structure of the bromodomain of human CREBBP in complex with an oxazepin ligand== | |
| + | <StructureSection load='4nr6' size='340' side='right'caption='[[4nr6]], [[Resolution|resolution]] 1.66Å' scene=''> | ||
| + | == Structural highlights == | ||
| + | <table><tr><td colspan='2'>[[4nr6]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4NR6 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4NR6 FirstGlance]. <br> | ||
| + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.66Å</td></tr> | ||
| + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=2LN:1-[7-(3,4-DIMETHOXYPHENYL)-9-{[(3R)-1-METHYLPIPERIDIN-3-YL]METHOXY}-2,3-DIHYDRO-1,4-BENZOXAZEPIN-4(5H)-YL]PROPAN-1-ONE'>2LN</scene></td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4nr6 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4nr6 OCA], [https://pdbe.org/4nr6 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4nr6 RCSB], [https://www.ebi.ac.uk/pdbsum/4nr6 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4nr6 ProSAT]</span></td></tr> | ||
| + | </table> | ||
| + | == Disease == | ||
| + | [https://www.uniprot.org/uniprot/CBP_HUMAN CBP_HUMAN] Note=Chromosomal aberrations involving CREBBP may be a cause of acute myeloid leukemias. Translocation t(8;16)(p11;p13) with KAT6A; translocation t(11;16)(q23;p13.3) with MLL/HRX; translocation t(10;16)(q22;p13) with KAT6B. KAT6A-CREBBP may induce leukemia by inhibiting RUNX1-mediated transcription. Defects in CREBBP are a cause of Rubinstein-Taybi syndrome type 1 (RSTS1) [MIM:[https://omim.org/entry/180849 180849]. RSTS1 is an autosomal dominant disorder characterized by craniofacial abnormalities, broad thumbs, broad big toes, mental retardation and a propensity for development of malignancies.<ref>PMID:11331617</ref> <ref>PMID:12114483</ref> <ref>PMID:12566391</ref> <ref>PMID:15706485</ref> | ||
| + | == Function == | ||
| + | [https://www.uniprot.org/uniprot/CBP_HUMAN CBP_HUMAN] Acetylates histones, giving a specific tag for transcriptional activation. Also acetylates non-histone proteins, like NCOA3 and FOXO1. Binds specifically to phosphorylated CREB and enhances its transcriptional activity toward cAMP-responsive genes. Acts as a coactivator of ALX1 in the presence of EP300.<ref>PMID:9707565</ref> <ref>PMID:11154691</ref> <ref>PMID:12738767</ref> <ref>PMID:12929931</ref> | ||
| - | + | ==See Also== | |
| - | + | *[[CREB-binding protein 3D structures|CREB-binding protein 3D structures]] | |
| - | + | == References == | |
| + | <references/> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
| + | [[Category: Homo sapiens]] | ||
| + | [[Category: Large Structures]] | ||
| + | [[Category: Arrowsmith CH]] | ||
| + | [[Category: Bountra C]] | ||
| + | [[Category: Brennan P]] | ||
| + | [[Category: Chaikuad A]] | ||
| + | [[Category: Edwards AM]] | ||
| + | [[Category: Fedorov O]] | ||
| + | [[Category: Felletar I]] | ||
| + | [[Category: Filippakopoulos P]] | ||
| + | [[Category: Hay D]] | ||
| + | [[Category: Knapp S]] | ||
| + | [[Category: Martin S]] | ||
| + | [[Category: Picaud S]] | ||
| + | [[Category: Von Delft F]] | ||
Current revision
Crystal structure of the bromodomain of human CREBBP in complex with an oxazepin ligand
| |||||||||||
Categories: Homo sapiens | Large Structures | Arrowsmith CH | Bountra C | Brennan P | Chaikuad A | Edwards AM | Fedorov O | Felletar I | Filippakopoulos P | Hay D | Knapp S | Martin S | Picaud S | Von Delft F
